EP Patent

EP4548935A2 — Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Assigned to Janssen Pharmaceutica NV · Expires 2025-05-07 · 1y expired

What this patent protects

Described herein methods of treating urothelial carcinoma with an approved drug product containing a fibroblapst growth factor receptor (FGFR) inhibitor. Also described herein are methods of selling or offering for sale an approved drug product containing a fibroblast growth fact…

USPTO Abstract

Described herein methods of treating urothelial carcinoma with an approved drug product containing a fibroblapst growth factor receptor (FGFR) inhibitor. Also described herein are methods of selling or offering for sale an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP4548935A2
Jurisdiction
EP
Classification
—
Expires
2025-05-07
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.